<DOC>
	<DOCNO>NCT01613521</DOCNO>
	<brief_summary>This study ass patient respond treatment cervical cancer . This research involve specific treatment cancer recommend doctor may include radiation therapy and/or chemotherapy . This separate research imaging study design assess patient respond treatment cervical cancer .</brief_summary>
	<brief_title>Tumor Perfusion Hypoxia Assessed DCE-MRI 18F-FMISO PET Biomarkers Treatment Response Cervical Cancer</brief_title>
	<detailed_description />
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Misonidazole</mesh_term>
	<criteria>Biopsydocumented , newlydiagnosed primary cervical cancer histopathology type . Clinically visible gross lesion ( International Federation Gynecology Obstetrics ( FIGO ) stage IB1 ) . Treatment ( chemoradiation ) , DCEMRI 18FFMISO PET study MSKCC . Patients must adult female 18 year age old . Patients general medical psychiatric condition , physiologic status give inform consent . Patients receive prior radiation treatment pelvis . Patients contraindication DCEMRI ( noncompatible cardiac pacemaker intracranial vascular clip , allergy Gadolinium , endstage renal disease ) and/or 18FFMISO PET . Patients fulfill screen criterion safe DCEMRI 18FFMISO PET per Department Radiology guideline . Pregnant patient ; patient breastfeed baby .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>DCE-MRI</keyword>
	<keyword>18F-FMISO PET</keyword>
	<keyword>11-174</keyword>
</DOC>